Cost-effectiveness of Out-of-Hospital Continuous Positive Airway Pressure for Acute Respiratory Failure by Thokala, P. et al.
EMERGENCY MEDICAL SERVICES/ORIGINAL RESEARCHCost-effectiveness of Out-of-Hospital Continuous Positive
Airway Pressure for Acute Respiratory Failure
Praveen Thokala, MASc, PhD*; Steve Goodacre, FCEM, PhD; Matt Ward, MCPara;
Jerry Penn-Ashman, Dip IMC RCSEd; Gavin D. Perkins, MD, FRCP
*Corresponding Author. E-mail: p.thokala@shefﬁeld.ac.uk.556 AnnStudy objective: We determine the cost-effectiveness of out-of-hospital continuous positive airway pressure (CPAP)
compared with standard care for adults presenting to emergency medical services with acute respiratory failure.
Methods: We developed an economic model using a United Kingdom health care system perspective to compare the
costs and health outcomes of out-of-hospital CPAP to standard care (inhospital noninvasive ventilation) when applied to
a hypothetical cohort of patients with acute respiratory failure. The model assigned each patient a probability of
intubation or death, depending on the patient’s characteristics and whether he or she had out-of-hospital CPAP or
standard care. The patients who survived accrued lifetime quality-adjusted life-years (QALYs) and health care costs
according to their age and sex. Costs were accrued through intervention and hospital treatment costs, which depended
on patient outcomes. All results were converted into US dollars, using the Organisation for Economic Co-operation and
Development purchasing power parities rates.
Results: Out-of-hospital CPAP was more effective than standard care but was also more expensive, with an incremental
cost-effectiveness ratio of £20,514 per QALY ($29,720/QALY) and a 49.5% probability of being cost-effective at the
£20,000 per QALY ($29,000/QALY) threshold. The probability of out-of-hospital CPAP’s being cost-effective at the
£20,000 per QALY ($29,000/QALY) threshold depended on the incidence of eligible patients and varied from 35.4%
when a low estimate of incidence was used to 93.8% with a high estimate. Variation in the incidence of eligible patients
also had a marked inﬂuence on the expected value of sample information for a future randomized trial.
Conclusion: The cost-effectiveness of out-of-hospital CPAP is uncertain. The incidence of patients eligible for out-
of-hospital CPAP appears to be the key determinant of cost-effectiveness. [Ann Emerg Med. 2015;65:556-563.]
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Background
Acute respiratory failure is a common but life-threatening
medical emergency, especially in elderly patients with
respiratory and cardiac diseases.1-3 Inhospital noninvasive
ventilation is widely used to treat acute respiratory failure
that is refractory to initial medical therapy.4-12 However, the
delay in providing noninvasive ventilation until arrival at the
hospital may be one factor explaining why the risk of death
in patients with respiratory problems increases markedly
with distance traveled to the hospital.13 It has been argued
that noninvasive ventilation is more likely to be effective if
used early in the course of respiratory failure, before fatigue
develops.14 Recent reviews have indicated that out-of-
hospital noninvasive ventilation is feasible and beneﬁcial inals of Emergency Medicineselected patients with acute respiratory failure.15-18 We have
undertaken a meta-analysis19 suggesting that out-of-hospital
continuous positive airway pressure (CPAP) has the best
evidence of effectiveness. CPAP is also the most practical
way of providing out-of-hospital noninvasive ventilation.
Importance
In the United States, the National Association of
Emergency Medical Services Physicians stated that
noninvasive ventilation is an important treatment modality
for the out-of-hospital management of acute dyspnea.20
The recent UK Ambulance Services Clinical Practice
Guidelines 201321 recommended (for the ﬁrst time) the use
of CPAP in the out-of-hospital environment on the basis
of expert consensus. However, use of out-of-hospitalVolume 65, no. 5 : May 2015
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What is already known on this topic
Emergency medical services (EMS) often use
continuous positive airway pressure (CPAP) to treat
out-of-hospital acute respiratory failure.
What question this study addressed
Is out-of-hospital CPAP cost-effective?
What this study adds to our knowledge
In this cost-effectiveness analysis using a
United Kingdom perspective, the incremental
cost-effectiveness ratio (£20,514 [$29,720] per
quality-adjusted life-year gained) was insufﬁcient by
British standards to support widespread CPAP
implementation. Interpretation of cost-effectiveness
may vary by country, including the US.
How this is relevant to clinical practice
Although not directly impacting clinical practice,
these ﬁndings highlight factors that should be
considered in the selection and implementation of
EMS therapies.CPAP in the United Kingdom remains limited in practice,
probably reﬂecting the signiﬁcant costs of establishing this
treatment. The decision to establish out-of-hospital CPAP
depends on weighing the beneﬁts of improved outcomes
against the additional costs incurred by establishing the
service and is fundamentally an issue of cost-effectiveness.
Goals of This Investigation
We aimed to estimate the incremental cost per quality-
adjusted life-year (QALY) of out-of-hospital CPAP
compared with standard care and determine whether out-
of-hospital CPAP should be recommended for funding
according to accepted thresholds for cost-effectiveness.22
MATERIALS AND METHODS
Theoretical Model of the Problem
The cost-effectiveness of a more effective and expensive
treatment, such as out-of-hospital CPAP, can be estimated
by comparing the outcomes and costs associated with the
treatment to an appropriate alternative, such as inhospital
noninvasive ventilation. Modeling is used to estimate how
better effectiveness leads to improved patient outcomes
relative to the cost of the care, expressed in terms of QALYs
gained by using the intervention. A QALY is equivalent to aVolume 65, no. 5 : May 2015year of life spent in full health and incorporates both quality of
life and survival. If outcomes are measured as QALYs, then
the incremental cost-effectiveness ratio, or cost per QALY
gained, can be calculated and compared with alternative uses
of health care funding. The incremental cost-effectiveness
ratio can be crudely understood as the amount needed for the
intervention to “buy” each additional QALY compared with
standard care. In the United Kingdom, the National Institute
for Health and Care Excellence typically recommends in
favor of funding interventions with an incremental cost-
effectiveness ratio below a threshold, widely accepted to be
between £20,000 and £30,000 per QALY (ie, interventions
that can be used to buy QALYs for less than £20,000
[$29,000] or £30,000 [$43,500] each) and recommends
against funding interventions with an incremental cost-
effectiveness ratio above these thresholds.22 Other countries
use different thresholds; one of $50,000 is conventionally
used in the United States. We used the National Institute for
Health and Care Excellence threshold because our analysis
took a UK perspective and was based on UK practice and
unit costs. Appendix E1 (available online at http://www.
annemergmed.com) describes the general principles of cost-
effectiveness analysis.
Study Design
We developed an economic model with the statistical
software program R23 (version 3.0.3) to explore the costs
and health outcomes associated with the use of out-of-
hospital CPAP to treat acute respiratory failure compared
with standard care, and to calculate the incremental cost per
QALY gained. We based the analysis on a UK health care
system perspective using a lifetime horizon. We converted
the results into US dollars, using the Organisation for
Economic Co-operation and Development purchasing
power parities rates (£1¼$1.45).
The structure of the model is shown in Figure 1 and the
parameters used in the model are reported in Table 1.
Patients in acute respiratory failure may receive either out-
of-hospital CPAP or standard care, so these alternative
treatments were applied to a hypothetical cohort of patients
with acute respiratory failure who were eligible for
noninvasive ventilation, ie, all patients receive out-of-
hospital CPAP in the intervention group and standard care
in the comparator group. Each patient in the model could
have one of the following outcomes: hospitalized without
intubation, hospitalized with intubation, or death in the
ambulance or hospital. The probability of death and
probability of intubation depended on whether the patient
received out-of-hospital CPAP or standard care. The
patients who survived accrued lifetime QALYs and health
care costs according to their life expectancy. Costs were alsoAnnals of Emergency Medicine 557
Figure 1. Model structure. CPAP, Continuous positive airway pressure.
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CPAP) and hospital treatment costs, which depended on
whether the patient needed intubation. Details of each of
these processes are outlined below.
We estimated the baseline risks of intubation and death
(ie, for patients receiving standard care)withdata frompublished
studies.19 We modeled the mortality risk of emergency
admissions with respiratory illness with a large cohort data set of
668 patients presenting with “respiratory disease” across 4
English ambulance services during a 4-year period, from 1997
to 2001.13 There were 79 deaths in 668 patients, which resultedTable 1. Summary of model parameters.*
Parameter Mean
Baseline risks
General population mean 30-day mortality probability 0.118
Risk of intubation 0.029
OR for out-of-hospital CPAP
Mortality 0.43
Intubation 0.32
Life expectancy of patients
Lifetime years 2.67
Health-related quality of life
Utility 0.6
Costs, £ ($)
Out-of-hospital CPAP 1,212 (1,740)
Hospitalization 2,250 (3,260)
Intubation 3,500 (5,075)
Annual 5,360 (7,685)
3CPO, Three Interventions in Cardiogenic Pulmonary Oedema24; NHS, National Health Se
*Beta (a,b) Distribution is a statistical distribution deﬁned between 0 and 1; a and b parame
its complement, eg, Beta (79,589) for mortality represents 79 deaths in a population of 668
values in the distribution lying between 2 SDs on either side of the mean, eg, normal (2.6
Distribution, where a is the shape parameter and b is the scale parameter, is typically used
of the samples of distribution Gamma (75,30) is 2,250 (7530).
558 Annals of Emergency Medicinein a mean mortality rate of 11.8%. This baseline mortality
rate is similar to that in the more recent Three Interventions
in Cardiogenic Pulmonary Oedema (3CPO) study.24
We modeled the risk of intubation for respiratory illness
with the data from 3CPO study,24 a multicenter, open,
prospective, randomized, controlled trial of 1,069 patients
presenting with severe acute cardiogenic pulmonary edema
at 26 emergency departments (EDs) in the UK. The study
reported amean intubation rate of 2.9%,which is similar to the
intubation rates of 2.7% reported in British Thoracic Society
national respiratory audit program annual report 2011/12.25Distribution Source
Beta (79, 589) Nicholl et al13
Beta (4.45, 150) 3CPO,24 clinical opinion
Samples Meta-analysis19
Samples Meta-analysis19
Normal (2.67, 0.16) 3CPO,24 clinical opinion
Beta (640, 425) 3CPO,24 clinical opinion
1,500–1,000b (2, 5) Clinical input
Gamma (75, 30) NHS reference costs30
Gamma (70, 50) NHS reference costs 2011–201230
Gamma (53, 100) NHS reference costs 2011–201230
rvice.
ters in the Beta distribution can be thought of as counts of the event of interest versus
(ie, 79þ589). Normal distribution is represented with mean and SD, with 95% of the
7, 0.16) implies that 95% of the samples lie between 2.35 and 2.99. Gamma (a,b)
for skewed distributions and has a mean expected value of ab, eg, the average value
Volume 65, no. 5 : May 2015
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reducingmortality and intubation as odds ratios (ORs) from a
meta-analysis19 of 6 randomized trials, which are summarized
in Table 1. The effectiveness estimates from ourmeta-analysis
are similar to those of Williams et al18 but greater than
those of Mal et al17 because the latter authors estimated
effectiveness for all forms of out-of-hospital noninvasive
ventilation together, whereas we estimated effectiveness of
out-of-hospital CPAP and bi-level inspiratory positive airway
pressure separately and used only the estimate for CPAP.
The patients who survived (ie, who avoided the short-term
mortality risk) accrued QALYs, and these lifetime QALYs
were estimated according to patients’ life expectancy and their
utilities. The life expectancy of patients with acute respiratory
failure and admitted to the hospital were captured from the
3CPO trial24 and parameterized as a normal distribution
with a mean of 2.67 and SD of 0.16, after discussions with a
clinical expert group (S.G., M.W., J.P.-A., and G.D.P.). The
3CPO study24 reported that the mean utility value (quality
of life) was 0.6. The estimated QALYs for patients with acute
respiratory failure were estimated bymultiplying the life-years
by the lifetime quality of life shown in Table 1. There was no
evidence that patients who survived after receiving out-of-
hospital CPAP experienced better health-related quality of life
or lived longer compared with patients given standard care.
We assumed that the lifetime QALYs were same for all
survivors, irrespective of whether they were in standard care or
the out-of-hospital CPAP arm.
The costs included in the model are for of out-of-hospital
CPAP, intubation, hospitalization, and lifetime care for
patients. Hubble et al26 reported a mean additional 5 days in
length of stay associated with intubation compared with that
for patients without intubation. We assumed that the
additional 5 hospital days spent by the intubated patients
would be in the ICU, according to the suggestions by the
clinical expert group, at a cost of £700 ($1,015) per day. We
estimated lifetime costs of survivors by using the annual costs
and the discounted life expectancy of patients captured from
the 3CPO trial.24 The study reported that mean costs in
months 4 to 6 were £1,341 ($1,944.50), which resulted in
mean annual costs of £5,360 ($7,685). The costs of standard
care were not included in the model because the analysis is
based on incremental costs, ie, we assumed that all initial
treatment costs were the same in both arms, regardless of
whether the patient received out-of-hospital CPAP.
We estimated the costs of out-of-hospital CPAP at an
ambulance service level and converted these into a cost per
patient according to a 5-year depreciation period. These costs
included those for initial equipment, implementation, and
ongoing maintenance. Although the costs of setting up the
service are largely the same, there are substantially differentVolume 65, no. 5 : May 2015estimates of incidence reported in different sources.25-29
The cost of out-of-hospital CPAP per patient in an
ambulance service is estimated to be £189.93þ£202,446/N
($275.50þ$293,546/N), where N is the number of
patients per ambulance service in a year. This information was
synthesized into a mean cost of £1,212 ($1,740) per patient,
according to our clinical expert input. Because there are
different estimates of incidence, ranging from approximately
175 to 2,000 patients per ambulance service in a year,
scenario analysis was also conducted for 3 different estimates
for unit cost for performing out-of-hospital CPAP per patient
(for different estimates of the eligible population), ie, a high-
cost scenario with a unit cost of £1,400 ($2,030), a low-cost
scenario with a unit cost of £745 ($1,080), and a lower-cost
scenario with a unit cost of £300 ($435). Full details are
provided in Appendix E2 (available online at http://www.
annemergmed.com).Primary Data Analysis
Probabilistic analysis incorporated uncertainty in the
parameter estimates to provide a measure of precision
and conﬁdence in the estimates of the mean costs and
QALYs. Additionally, we calculated the probability that
each strategy would be the most cost-effective at different
thresholds for willingness to pay for health gain. We
constructed cost-effectiveness acceptability curves by
plotting the probability of each strategy’s being cost-
effective against willingness to pay. Furthermore, expected
value of perfect information was estimated to identify
whether the expected cost of future research would be
valuable. Expected value of partial perfect information and
expected value of sample information techniques were also
used to identify the critical areas of uncertainty in which
future research would produce the most beneﬁt. Value-
of-information analyses (expected value of perfect
information, expected value of partial perfect information,
and expected value of sample information) provide an
estimate of the monetary value of further research to reduce
uncertainty and, in particular, an estimate of how much we
should be prepared to pay for a trial to reduce uncertainty.RESULTS
The total costs of out-of-hospital CPAP are higher than
those of usual care (£16,895 versus £14,863, or $24,497
versus $21,551), but 0.099 QALYs are gained per patient
treated (1.513 versus 1.414). The mean incremental
cost-effectiveness ratio of out-of-hospital CPAP compared
with standard care in the base case analysis is £20,514 per
QALY ($29,720/QALY). It therefore costs the health
service £20,514 ($29,720) to buy each additional QALYAnnals of Emergency Medicine 559
Figure 2. Cost-effectiveness plane for the base-case economic analysis. ICER, Incremental cost-effectiveness ratio; QALY, quality-
adjusted life-years.
Cost-effectiveness of CPAP for Acute Respiratory Failure Thokala et alwith out-of-hospital CPAP. Figure 2 shows the uncertainty
associated with this estimate by plotting samples of mean
incremental costs and QALYs. There is substantial
uncertainty, with samples falling equally on either side of
the red line, indicating the £20,000 per QALY ($29,000/
QALY) threshold and a 49.5% probability of out-of-
hospital CPAP’s being cost-effective at this threshold.
This is also observed in the cost-effectiveness analysis curve
in Figure 3, which shows the proportion of model runs for
which each strategy is cost-effective over a range of potential
thresholds for willingness to pay. The more we are willing to
pay for health gain (ie, themore we are willing to spend to buy
a QALY), the more likely it is that out-of-hospital CPAP will
be cost-effective, but there is substantial uncertainty between
the thresholds of £20,000 per QALY ($29,000/QALY) and
£30,000 per QALY ($43,500/QALY).Figure 3. Cost-effectiveness acceptability curve for the base-
case economic analysis.
560 Annals of Emergency MedicineScenario analysis was also conducted for 3 different
estimates for unit cost for providing out-of-hospital CPAP
per patient, ie, a high-cost scenario with a unit cost of
£1,400 ($2,030), a low-cost scenario with a unit cost of
£745 ($1,080), and a lower-cost scenario with a unit cost
of £300 ($435). These estimates reﬂect variation in our
estimates of the incidence of appropriate patients, with high
estimates of incidence resulting in lower estimated costs.
Table 2 compares each scenario with the base case and
shows that out-of-hospital CPAP is more likely to be cost-
effective (93.8% probability) if the incidence of appropriate
patients is high and the resulting cost per patient low.
Results from threshold analysis suggested that CPAP is
unlikely to be cost-effective at £30,000 per QALY
($43,500/QALY) in an ambulance service is greater than if
it costs more than £2,170 ($3,150) for out-of-hospital
CPAP per patient.
The incidence of appropriate patients was also an important
determinant of the expected value of information. The
population expected value of perfect information at the
threshold of £20,000 per QALY ($29,000/QALY) is £1.9
million ($2.75million) at a low estimate of incidence of 3.5 per
100,000 population per year and£22.5million ($32.5million)
at a higher incidence of 40.8 per 100,000 population per year.
This value is deﬁned as the maximum investment
a decisionmaker would be willing to pay to eliminate all
parameter uncertainty from the decision problem and reﬂects
the amount we should be willing to pay for research to reduce
uncertainty. Expected value of partial perfect information
analysis suggested baseline mortality, out-of-hospital CPAP
mortality OR, and costs of out-of-hospital CPAP as the
key parameters driving uncertainty. The population expectedVolume 65, no. 5 : May 2015
Table 2. Results for different cost scenarios.
Scenario
Type, £ ($)
Standard Care Out-of-Hospital CPAP
Differences
Between Out-of-Hospital
CPAP and Standard Care
ICER
(per QALY), £ ($)
Probability
of being
Cost-effective
Total
Costs, £ ($)
Total
QALYs
Total
Costs, £ ($)
Total
QALYs Costs, £ ($) QALYs
Base case 14,863 (21,551) 1.414 16,895 (24,498) 1.513 2,032 (2,946) 0.099 20,514 (29,720) 0.495
High cost, 1,400 (2,030)* 14,863 (21,551) 1.414 17,078 (24,763) 1.513 2,216 (3,213) 0.099 22,368 (32,434) 0.354
Low cost, 745 (1,080)* 14,863 (21,551) 1.414 16,421 (23,810) 1.513 1,558 (2,259) 0.099 15,728 (22,805) 0.798
Lower cost, 300 (435)* 14,863 (21,551) 1.414 15,977 (23,166) 1.513 1,114 (1,615) 0.099 11,248 (16,309) 0.938
*Scenario analysis was conducted for different estimates for unit cost for performing out-of-hospital CPAP per patient (for different estimates of the eligible population). See
Appendix E2 (available online at http://www.annemergmed.com) for more details.
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together at the threshold is estimated as £1.83 million
($2.65 million) at the low incidence and £21.3 million ($30.8
million) at the higher one, both of which are very close to the
population expected value of perfect information values,
suggesting that most of the uncertainty in the decision problem
is from these 3 parameters. The population expected value of
sample information value for baseline mortality and out-of-
hospital CPAP mortality OR parameters, assuming a
randomized controlled trial with 100 patients in each arm, is
estimated as £1.08million ($1.56million) at low incidence and
£12.67 million ($18.37 million) at the higher one. It is cost-
effective to conduct the trial to address the uncertainty if the
population expected value of sample information of a proposed
trial at a given sample size is greater than the costs of the trial.LIMITATIONS
This model is generally based on robust data sources, with
the estimates of effectiveness of out-of-hospital CPAP being
derived from a meta-analysis of randomized trials and most
cost estimates being derived from UK National Health
Service reference costs. However, there are some limitations
to the data. The trials in the meta-analysis were generally
small and had potentially selected study populations, which
may not have compared out-of-hospital CPAP with best
alternative care. The model parameters were estimated from
different sources, which may include different patient
populations; for example, the baseline mortality risk was
estimated for patients with respiratory disease, whereas the
intubation risk was based on data for patients with a
diagnosis of severe acute cardiogenic pulmonary edema.
The perspective of the analysis was the English health
service, UK cost estimates were used, key model parameters
were estimated from UK sources, and the thresholds for
cost-effectiveness were those used in the United Kingdom
by the National Institute for Health and Care Excellence.
Costs may differ in other countries; for example, the unitVolume 65, no. 5 : May 2015cost of the CPAP system may be lower in the United States.
The cost-effectiveness of out-of-hospital CPAP may be
more certain in health services with different parameters of
willingness to pay for health gain. In particular, cost-
effectiveness appears to be more certain when compared
against a US threshold of $50,000 per QALY. However,
our analysis used UK estimates of costs and resource use. If
costs and resource use are higher in the United States, the
cost-effectiveness will be less certain.
The cost per patient of providing out-of-hospital CPAP
was calculated by dividing the total cost of setting up and
running the service by the total number of patients treated,
which means that the cost per patient was determined by
the incidence of patients who were likely to beneﬁt from
out-of-hospital CPAP. We identiﬁed a number of sources
for our estimate of this parameter, but these estimates
varied markedly. Sensitivity analysis showed that cost per
patient is an important determinant of cost-effectiveness, so
an accurate estimate of the incidence of patients likely to
beneﬁt from out-of-hospital CPAP is required to accurately
estimate cost-effectiveness.
We have assumed in the analysis that the ambulance
service has a 1-tiered response. However, some services may
have different tiers of response that may allow more efﬁcient
use of equipment and trained staff. We assumed that out-
of-hospital CPAP had a constant effect on mortality and
intubation rate, according to estimates from meta-analysis.
Effectiveness may depend on distance traveled to the hospital,
being more effective in settings with long distances to the
hospital. Unfortunately, distance to the hospital was not
consistently collected in primary studies, so this factor could
not be explored in the individual patient data meta-analysis.19DISCUSSION
The economic analysis showed that out-of-hospital
CPAP was more effective than standard care, with 0.099
QALYs gained per patient treated, but was more expensive,Annals of Emergency Medicine 561
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treated. The incremental cost-effectiveness ratio for out-of-
hospital CPAP was £20,514 per QALY ($29,720/QALY)
compared with standard care, with 49.5% probability of
being cost-effective at the £20,000 per QALY threshold.
These ﬁndings suggest that even if the apparent
effectiveness of out-of-hospital CPAP reported by recent
meta-analysis17,18 were conﬁrmed, the cost-effectiveness of
this treatment is uncertain when compared with a UK cost-
effectiveness threshold. It is therefore unlikely that out-of-
hospital CPAP would be recommended for widespread
implementation in the United Kingdom on the basis of this
analysis.
In developing the economic model, we identiﬁed marked
variation between estimates from different sources of the
incidence of patients likely to beneﬁt from out-of-hospital
CPAP. Sensitivity analysis showed that this parameter was
an important determinant of cost-effectiveness, with the
probability of out-of-hospital CPAP’s being cost-effective at
the £20,000 per QALY ($29,000/QALY) threshold varying
from 35.4% to 93.8%. Most of the costs of providing out-
of-hospital CPAP are incurred in setting up the service. If
only a small number of patients will beneﬁt from out-of-
hospital CPAP, then the cost per patient will be high and
cost-effectiveness is unlikely.
We identiﬁed only 1 previous economic analysis of out-
of-hospital CPAP.25 This was undertaken in the United
States and estimated that out-of-hospital CPAP would save
0.75 additional lives per 1,000 patients, at a cost of $490
per life saved. This analysis had a number of limitations.
Treatment effect estimates were based on trial of inhospital
rather than out-of-hospital CPAP, so the analysis effectively
compared CPAP with no noninvasive ventilation, rather
than comparing out-of-hospital CPAP with inhospital
noninvasive ventilation. Outcomes were valued as lives
saved rather than QALYs, and the model used only a 1-year
time horizon. One-way sensitivity analysis was performed,
but the authors did not perform a probabilistic sensitivity
analysis. The estimate that out-of-hospital CPAP would be
used 4 times per 1,000 patients seems high compared with
our estimates of patient eligibility. As a consequence,
although this analysis suggested that out-of-hospital CPAP
is cost-effective, it is unlikely to convince purchasers of
health care.
Expected value of information analysis was undertaken
to explore uncertainty and determine the value of further
research. It showed that the value of undertaking a trial
depends on the estimated incidence of eligible patients.
The maximum cost at which it would be cost-effective to
conduct a trial with 100 patients in each arm is only £1.08
million ($1.56 million) if there were a low estimated562 Annals of Emergency Medicineincidence (of 3.5 per 100,000 population per year) of
eligible patients, but would be £12.67 million ($18.37
million) if there were a high estimated incidence (of 40.8
per 100,000 population per year). A more precise estimate
of the incidence of eligible patients is therefore required to
determine the cost-effectiveness of a future trial of out-of-
hospital CPAP. Of course, the feasibility of a future trial
would also depend on the incidence of eligible patients.
Our model can be used to determine whether out-of-
hospital CPAP is likely to be cost-effective in a particular
system, given the estimate of the incidence of eligible
patients. Our analysis indicates that out-of-hospital CPAP
has uncertain cost-effectiveness. Establishing out-of-hospital
CPAP as a standard treatment of acute respiratory failure
will require substantial resources, and there is a relatively
high probability that outcomes improvements from out-
of-hospital CPAP may not be justiﬁed by the ﬁnancial
investment. A large pragmatic randomized trial could
improve our estimates of effectiveness and cost-effectiveness,
but this would also require substantial funding, with
uncertain value. Our analysis suggests that the incidence
of patients eligible for out-of-hospital CPAP is an important
determinant of the cost-effectiveness of out-of-hospital
CPAP itself and of a future trial of it. Health systems
considering implementing out-of-hospital CPAP should ﬁrst
estimate the incidence of potentially eligible patients. If the
incidence is low, then implementation of out-of-hospital
CPAP is not likely to be cost-effective. If the incidence is
high, then implementation or further research with a large
pragmatic randomized trial may be appropriate. If incidence
varies between health care systems, then out-of-hospital
CPAP may be cost-effective in some systems but not others.
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Methods to estimate cost-effectiveness
The cost-effectiveness of the different interventions
was estimated with both the ICER and the net beneﬁt
approaches. Uncertainty was incorporated in the
modeling by performing probabilistic sensitivity analysis.
Descriptions of these terms and approaches are provided in
the sections below.Deﬁnitions of Cost-effectiveness Terms
The ICER measures the relative value of 2 strategies and
is calculated as the mean incremental cost divided by the
mean incremental beneﬁts. A strategy is dominated
when another strategy accrues more QALYs for less cost.
Extended dominance occurs when a combination of 2
alternative strategies can produce the same QALYs as a
chosen strategy but at a lower cost. Strategies that are
neither dominated nor extendedly dominated constitute
the cost-effectiveness frontier, and the ICER is reported for
these strategies compared with the next least effective
strategy. The willingness-to-pay threshold is the amount
of money that the decisionmaker is willing to pay to
gain 1 additional QALY. The usual threshold for
decisionmaking at the United Kingdom National Institute
for Care Excellence is considered to be approximately
£20,000 to £30,000 per QALY. The net monetary beneﬁt
is deﬁned as the QALYs multiplied by a value for the
QALYs (eg, £20,000) minus the costs of obtaining them,
that is, net monetary beneﬁt¼QALYsl–cost, where l is
the willingness-to-pay threshold. The net monetary beneﬁt
approach is simpler to calculate and gives equivalent
ﬁndings (but requires an explicit assumption about the
value of l).Uncertainty Analysis
The results presented in the following section include
the effects of accounting for uncertainty in the model
parameters (the costs, utilities, risks, and ORs for mortality
and intubation), characterized as probability distributions.
Probabilistic sensitivity analysis is undertaken whereby the
model is rerun (1,000 times), each time with a different
value for the risks, ORs, costs, and utilities, sampled from
the probability distributions. The cost-effectiveness plane
shows the incremental costs (y axis) and incremental
QALYs (x axis) compared with usual care. In this chart, if a
model run for a strategy had exactly the same costs and
QALYs as usual care, then the “sample” for that model run
would appear at the origin. Samples plotted to the right of
the y axis have more QALYs than usual care and samples
plotted above the x axis have more costs. Samples plotted to563.e1 Annals of Emergency Medicinethe right of a straight line with slope l passing through the
origin are cost-effective, whereas those plotted to the left are
not. The cost-effectiveness acceptability curve shows the
proportion of model runs for which each strategy is cost-
effective over a range of potential willingness-to-pay
thresholds (ie, l).
Value of Information Analysis
Another measure of uncertainty is the overall expected
value of perfect information (EVPI). This calculation is
carried out according to the theory that the decisionmaker
will choose the most cost-effective option but could acquire
additional evidence to reduce the uncertainties in the
decision; for example, know exactly what the ORs for
mortality and hospitalizations are for each treatment. In the
EVPI calculation, it can be estimated how often making the
decision based on current evidence could be wrong, and
also how many QALYs (and costs) would be lost by
choosing the strategy that is expected to be most cost-
effective, given current evidence, when in fact one of the
other strategies is truly the most cost-effective. This can be
multiplied by the number of patients per year and the
expected lifetime of the decision to estimate the population
EVPI. The interpretation of population EVPI is that if one
could fund research to eliminate the uncertainty in
effectiveness for all of the parameters for each strategy (eg,
by a large or inﬁnitely large clinical trial), then the value of
eliminating the uncertainty through such research would be
expected to be the population EVPI. This can be thought
of as the maximum that the health care system should be
willing to pay for additional evidence to inform the
decision in the future and thus is an upper bound on the
value of conducting further research, ie, if the population
EVPI exceeds the expected costs of additional research,
then it is potentially cost-effective to conduct further
research.
Expected value of partial perfect information (EVPPI) is
similar to EVPI, but instead of evaluating the uncertainty
associated with all parameters it focuses on the
uncertainty associated with a subset of one or more
parameters, allowing the decisionmakers to conclude in
which variables further research would be most beneﬁcial.
The computational time required for EVPPI is markedly
more than for EVPI because the process essentially requires
2 iterations of probabilistic analyses, as standard
probabilistic sensitivity analyses are undertaken for each
sampled parameter value for the variable(s) under analysis.
If the population EVPPI for a subset of parameters exceeds
the expected costs of additional research, then it is
potentially cost-effective to conduct further research to
estimate those parameters.Volume 65, no. 5 : May 2015
Thokala et al Cost-effectiveness of CPAP for Acute Respiratory FailureExpected value of sample information (EVSI) addresses
the limitation of EVPI, which assumes parameters can be
ascertained without uncertainty (ie, effectively assuming an
inﬁnite trial size), and seeks to provide an optimal number
of patients to study within a future trial. In addition, EVSI
also allows the evaluation of marginal returns associated
with increased sample size formally taking uncertainty into
account (eg, say that an additional 100 patients when only
500 have been recruited would be likely to provide more
value than when 20,000 have been recruited). Within
EVSI, the costs of the trial are compared with the beneﬁts
achieved to ﬁnd the maximum expected net beneﬁt, which
would correspond with the recommended trial size. If the
population EVSI of a proposed trial is greater than the costs
of the trial, then it is cost-effective to conduct the trial to
address the uncertainty.APPENDIX E2.
Costs of out-of-hospital CPAP
There are a number of costs involved in providing out-
of-hospital CPAP, such as initial equipment costs,
implementation costs, and ongoing maintenance costs.
These costs were converted into a cost per patient
according to a 5-year depreciation period (ie, assuming that
new out-of-hospital noninvasive ventilation equipment will
be required in 5 years) and sharing the overall costs out
among the number of patients who would beneﬁt from the
service during this period.
Total Costs of Out-of-Hospital CPAP to the
Ambulance Service
The costs were often missing from the studies in
literature, and thus bottom-up costing methods were used
to estimate the costs of out-of-hospital CPAP. The
breakdown of the costs for out-of-hospital CPAP is shown
in Table E1 and is split into 3 main components:
 initial costs of the out-of-hospital CPAP devices
 setup/implementation costs, ie, staff training costs and
service reconﬁguration costs
 maintenance costs of the service, ie, consumables and
depreciation
The costs of the out-of-hospital CPAP devices were elicited
from the expert advisory group. The costs of implementation
on provider organizations were estimated with bottom-up
costing methods, assuming a typical ambulance service. The
maintenance costs were estimated with activity-based costing
for the resources spent on consumables, according to evidence
from the literature.
The out-of-hospital CPAP device can take different levels
of complexity, and the cost of the device is based on thisVolume 65, no. 5 : May 2015complexity. For example, the costs are different for the
noninvasive positive pressure ventilation devices and
CPAP/bi-level inspiratory positive airway pressure devices.
Furthermore, the costs also depend on whether the devices use
a cylinder or whether they are electrically or mechanically
powered. The costs of the device were elicited from the expert
advisory group, assuming a close-ﬁtting face mask CPAP
device with Boussignac CPAP system manufactured by Vygon
as the representative of a typical CPAP system. The Boussignac
Hospital CPAP kit costs £513.49 ($744.5) and contains the
equipment required to deliver out-of-hospital CPAP. We
assumed that each ambulance would have the equipment and
10% would need replacing during the 5-year period.
The costs of implementation on provider organizations
was estimated with bottom-up costing methods, assuming a
typical ambulance service, according to the mean size of
National Health Service ambulance services in the United
Kingdom. It was assumed that a typical ambulance service
would have an average capacity of 1,500 paramedics, which
was deemed sensible by the expert advisory group. They
also suggested that an average of 2 days needed to be
dedicated for paramedic training. The costs associated with
training were estimated by multiplying this paramedic time
with their daily rate according to the Personal and Social
Services Research Unit (PSSRU 2012).6 The daily cost per
working day was estimated as £150 ($217.5), assuming an
average salary of £40,000 ($58,000), including overheads if
they are in band 6/7, on suggestion by the clinical advisory
group. Service reconﬁguration costs were estimated as a
1-off cost of £100,000 ($145,000), and this included
the cost of developing new guidelines and pathways.
Installation costs were assumed to be zero because the
CPAP set under consideration is a disposable system.
The maintenance costs were estimated by using costing
for the resources spent on consumables according to
information from the manufacturers that the facial mask,
oxygen tubing, and valve (costing £189.93 [$275]) would
need to be replaced after each use, whereas the rest of the
equipment was reusable. The expert advisory group
suggested that an average of an additional day halfway
through the 5-year period would be required by the
paramedics for updating their training.
Number of Patients Receiving Out-of-Hospital CPAP
in a Typical Ambulance Service
The incidence of patients who will beneﬁt from out-of-
hospital CPAP is one of the key parameters in the
model because the unit cost of out-of-hospital CPAP is
estimated by dividing the total costs of out-of-hospital
CPAP to the ambulance service by the number of patients
treated. There are different estimates of incidenceAnnals of Emergency Medicine 563.e2
Table E1. Breakdown of out-of-hospital CPAP costs.
Number of Devices Source Unit Cost, £ ($) Source Total Cost, £ ($)
Device costs
Out-of-hospital CPAP
device
Number of
ambulances
that need the
CPAP device (420)
Expert advisory input 513.49 (744.50) Vygon: hospital CPAP kit 513.49420
Assuming 10% new
CPAP devices
during 5-y
usage (42)
Expert advisory input 513.49 (744.50) Vygon: hospital CPAP kit 513.4942
Total cost of the device 237,232
Setup/implementation costs
Resource Usage
Initial training 1,500 paramedics
for 2 days each
Expert advisory input 150 (217.50) per day Expert advisory input 450,000 (652,500)
Service reconﬁguration 1-off cost for reconﬁguration Expert advisory input 100,000 (145,000)
Total setup/implementation costs 550,000 (797,500)
Maintenance costs
Resource Usage
Consumables Number of patients
during 5 y¼5N
Expert advisory input 189.93 (275) per use Vygon: facial mask,
oxygen tubing, and valve
189.935N (2755N)
Ongoing training 1,500 paramedics
for 1 day each
Expert advisory input 150 (217.50) per day Expert advisory input 225,000 (326,500)
Total maintenance costs 225,000þ949.65N
(326,500þ1,375N)
Total costs of out-of-hospital CPAP 1,012,232þ949.65N
Total number of patients (N patients per year times depreciation period of 5 y
(ie, assuming new out-of-hospital CPAP equipment will be required in 5 y)
5N
Cost of out-of-hospital CPAP per patient 189.93þ202,446/N
(275.50þ293,546/N)
Cost-effectiveness of CPAP for Acute Respiratory Failure Thokala et alreported in different sources, as reported below, and these
are synthesized to achieve a distribution for the costs of
out-of-hospital CPAP.
Spijker et al1 reported that 16 patients received out-of-
hospital CPAP across 11 months in an ambulance service
covering a population of 500,000, which amounts into 3.5
potentially eligible cases per 100,000/year. This study
identiﬁed only patients with acute cardiogenic pulmonary
edema, and many eligible patients did not receive treatment
(which admittedly may reﬂect real life); hence, this could
be an underestimate of true incidence. Similarly, Aguilar
et al2 reported that 175 patients received out-of-hospital
noninvasive ventilation across 22 months in an ambulance
service covering a population of 1.3 million, which
amounts to 7.3 potentially eligible cases per 100,000/year.
Luhr et al3 estimated 77.6 cases of acute respiratory failure
per 100,000/year population. Of these, 13.7% were due to
chronic obstructive pulmonary disease and 9.2% were due to
cardiogenic pulmonary edema (ie, cases with potential to
beneﬁt from out-of-hospital noninvasive ventilation). Thus,
the incidence can be estimated as 17.8 potentially eligible cases
per 100,000/year. However, they are relatively old data and
include patients who developed acute respiratory failure in the
hospital, so they may be an overestimate.563.e3 Annals of Emergency MedicineThe British Thoracic Society National Respiratory
Audit Programme 2011/124 reported that 130 hospitals
submitted data on 2,490 patients with noninvasive
ventilation between February 1 and March 31, 2012 (ie, 2
months). This amounts to 19.15 (2,490/130) NIV patients
per hospital per month, which in yearly terms is 115 per
hospital. There are 168 acute hospitals in England serving a
population of 53.01 million, which yields an incidence of
36.4 per 100,000 population. However, the details of the
audit were not clear and may be subject to bias. Furthermore,
it included patients who developed acute respiratory failure in
the hospital so may be an overestimate.
In the Shefﬁeld TeachingHospital ED, there were 255 sets
of noninvasive ventilation equipment used during 1 year. This
hospital serves a population of 551,800, which amounts to
46.2 potentially eligible cases per 100,000/year. However, the
equipmentmaynot actually have been used for patient care, or
multiple pieces of equipmentmay have been used for the same
patient, so this is likely to be an overestimate.
Hubble et al5 estimated that there were 4 per 1,000
patients transported by ambulance who were eligible for
noninvasive ventilation. In 2011 to 2012, there were 4.53
million emergency ambulance transfers to a Level I or II
ED in England (population 53.01 million). If 4 per 1,000Volume 65, no. 5 : May 2015
Table E2. Scenarios for unit costs of out-of-hospital CPAP.
Source
Incidence of
Eligible Patients
per 100,000
Annual Eligible
Patients in an
Ambulance
Service
Unit Cost
of Out-of-Hospital
CPAP, £ ($)*
Spijker et al1 3.5 175 1,346.76 (1,952.80)
Aguilar et al2 7.3 365 744.58 (1,096.64)
Luhr et al3 17.8 890 417.40 (605.20)
Hubble et al5 34.2 1,700 309.02 (448.08)
BTS audit4 36.1 1,800 302.40 (438.48)
STH ED data 40.8 2,000 291.15 (422.15)
BTS, British Thoracic Society; STH, Shefﬁeld Teaching Hospital.
*Using the formula unit cost¼£189.93þ£202,446/N ($275.5þ$293,546/N), where
N is the number of patients per year.
Figure E1. Histogram of the distribution of CPAP costs.
Thokala et al Cost-effectiveness of CPAP for Acute Respiratory Failureof these were eligible, this suggests an incidence of 34.2 per
100,000 population.REFERENCES
1. Spijker EE, de Bont M, Bax M, et al. Practical use, effects and
complications of prehospital treatment of acute cardiogenic
pulmonary edema using the Boussignac CPAP system. Int J Emerg
Med. 2013;6:8.Scenarios for Costs of Out-of-Hospital CPAP to the
Ambulance Service
As stated above, there are substantially different estimates
of incidence reported in different sources, and they are
summarized in Table E2. A typical ambulance service caters
to a population of approximately 5 million, which suggests
a range from approximately 175 to 2,000 patients per
ambulance service in a year, depending on the estimate of
the incidence. Thus, scenario analysis was conducted by
estimating the unit cost for providing out-of-hospital CPAP
for these different estimates of the eligible population. The
unit costs for the different scenarios are presented in Table
E3. This information was synthesized into an expression for
the out-of-hospital CPAP costs as £1,500 to £1,000b (2,
5), shown in Figure E1. This was chosen because our clinical
experts believed that most of the samples of costs will fall
between £1,400 ($2,030) and £800 ($1,160), with only a
few instances in which the costs are lower than £800
($1,160).2. Aguilar SA, Lee J, Castillo E, et al. Assessment of the addition of
prehospital continuous positive airway pressure (CPAP) to an urban
emergency medical services (EMS) system in persons with severe
respiratory distress. J Emerg Med. 2013;45:210-219.
3. Luhr OR, Antonsen K, Karlsson M, et al. Incidence and mortality after
acute respiratory failure and acute respiratory distress syndrome in
Sweden, Denmark, and Iceland. The ARF Study Group. Am J Respir Crit
Care Med. 1999;159:1849-1861.High-Cost Scenario
Scenario analysis was conducted with a different
estimate for unit cost for performing out-of-hospital CPAP
per patient (assuming 175 patients in the ambulance service
as the eligible population for CPAP), a high-cost scenarioTable E3. Summary of costs.
Scenario
Mean
Value, £ ($) Distribution, £ ($)
Baseline 1,212 (1,740) 1,500–1,000b (2, 5)
High cost 1,400 (2,030) Normal (1,400, 100) [normal (2,030, 145)]
Low cost 745 (1,080) Normal (745, 100) [normal (1,080, 145)]
Lower cost 300 (435) Normal (300, 50) [normal (435, 72.50)]
Volume 65, no. 5 : May 2015with a unit cost of £1,400 ($2,030). The distribution used
is normal (£1,400, £100), ie, normal ($2,030, $145).
Low-Cost Scenario
Scenario analysis was also conducted with a different
estimate for unit cost for performing out-of-hospital CPAP
per patient (assuming 365 patients in the ambulance service
as the eligible population for CPAP), a low-cost scenario
with a unit cost of £745 ($1,080). The distribution used is
normal (£745, £100), ie, normal ($1,080, $145).
Lower-Cost Scenario
Scenario analysis was also conducted with a different
estimate for unit cost for performing out-of-hospital
CPAP per patient (assuming 1,700 to 2,000 patients in
the ambulance service as the eligible population for
CPAP), a low-cost scenario with a unit cost of £300
($435). The distribution used is normal (£300, £50), ie,
normal ($435, $72.50).4. British Thoracic Society. National Respiratory Audit Programme annual
report. 2012. Available at: https://www.brit-thoracic.org.uk/document-
library/audit-and-quality-improvement/audit-reports/bts-national-
respiratory-audit-programme-annual-report-2011-2012/. Accessed
May 1, 2013.
5. Hubble MW, Richards ME, Wilfong DA. Estimates of cost-effectiveness
of prehospital continuous positive airway pressure in the management
of acute pulmonary edema. Prehosp Emerg Care. 2008;12:277-285.
6. Personal Social Services. Unit costs of health and social care 2012.
Available at: http://www.pssru.ac.uk/archive/pdf/uc/uc2012/full-
with-covers.pdf. Accessed May 1, 2013.
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